Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection.
about
Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analysesIdentification of human papillomavirus type 16 L1 surface loops required for neutralization by human seraHuman papillomavirus and HPV vaccines: a reviewThe causal relation between human papillomavirus and cervical cancer.Characterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitopeHuman papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysisEUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infectionTrends in HPV cervical and seroprevalence and associations between oral and genital infection and serum antibodies in NHANES 2003-2012Human papillomavirus proteins are found in peripheral blood and semen Cd20+ and Cd56+ cells during HPV-16 semen infectionCross-sectional study of HPV-16 infection in a population-based subsample of Hispanic adults.Determinants of seropositivity among HPV-16/18 DNA positive young women.HPV infection and cervical disease: a review.Use of the normalized absorbance ratio as an internal standardization approach to minimize measurement error in enzyme-linked immunosorbent assays for diagnosis of human papillomavirus infectionRisk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors.Multiplexed serologic assay for nine anogenital human papillomavirus types.Serological prevalence and persistence of high-risk human papillomavirus infection among women in Santiago, Chile.Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers.Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18Incident cervical infections with high- and low-risk human papillomavirus (HPV) infections among mothers in the prospective Finnish Family HPV Study.Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women.Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions.Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes.The levels of anti-HPV16/18 and anti-HPV31/33/35/45/52/58 antibodies among AS04-adjuvanted HPV16/18 vaccinated and non-vaccinated Ugandan girls aged 10-16 yearsAssociation between toll-like receptor expression and human papillomavirus type 16 persistence.Associations between human papillomavirus and history of cancer among U.S. adults in the National Health and Nutrition Examination Survey (2003-2010)Seroprevalence of human papillomavirus types 6, 11, 16 and 18 in Chinese women.HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future.Detection of CD4(+)- and CD8(+)-T-cell responses to human papillomavirus type 1 antigens expressed at various stages of the virus life cycle by using an enzyme-linked immunospot assay of gamma interferon releaseFeasibility and acceptance of cervicovaginal self-sampling within the German National Cohort (Pretest 2)Changes in antibody seroprevalence of seven high-risk HPV types between nationwide surveillance studies from 1995-96 and 2006-07 in The Netherlands.Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study.Human papillomavirus seropositivity and subsequent risk of HIV acquisition in rural South African womenThe association of HPV-16 seropositivity and natural immunity to reinfection: insights from compartmental modelsA novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.Serological detection of human papillomavirus type 16 infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women.Human papilloma virus persistence and neopterin, folate and homocysteine levels in cervical dysplasias.Immune therapy for human papillomaviruses-related cancers.Patterns of human papillomavirus DNA and antibody positivity in young males and females, suggesting a site-specific natural course of infection.Development of therapeutic HPV vaccines.
P2860
Q21144710-842F8D8E-BCF1-488A-8D4C-854D6630E053Q24545868-C558462C-0988-400C-95CF-D1222AE6EBAFQ24657891-F5E1305E-D6C3-4BB4-8EA4-5A2F9C7DECC3Q24673148-A9EAE1D8-83BD-4B8A-A1D6-5BD6C012256EQ24796150-9520EDB7-EED3-4425-B39C-ECE33AC36527Q26863193-ED09D144-576E-47B1-8D82-5338B10B2721Q27010432-B3C24719-2857-4CDC-A4EC-0903E1EFA20DQ27312453-573BE842-7CB9-4F94-BC94-1BA7F0941380Q30561339-372C5DC4-4472-4AEF-A618-DAE3EC5DB2F9Q30571320-7A400F9F-C901-497B-BC14-6405241E0B4CQ30986936-7012AD40-CB70-4D2E-BDA2-D5E5434C4AAEQ33159907-41B7C572-CB79-49CC-9FC0-BD3CC65D1302Q33704870-2B6C733C-A074-49D0-B011-ED469B70A4F7Q33725156-201C0BE9-6F85-4BD9-B2E5-30543CD1966AQ33825698-3DCC47A0-1505-4CD6-8293-4108AA4F28E8Q33880956-D40C9002-5B2A-415E-A059-954B62B40DD8Q33908917-FC76986D-A5B7-456B-A405-B10F0DEBF043Q33910699-5AA953B9-DC9A-4A33-8A0B-B87F300EEC01Q33940157-AAABB057-2C47-4163-860C-20E0BD38EE33Q33944133-F9079C34-66A9-45D9-B571-A3246936D6FFQ33950282-25662EA6-0F60-4FE4-A450-B7DF6B45549AQ33953881-37F9509F-67C3-482F-82C1-77B17342D42FQ33974260-26DF17CE-CF21-48C1-B162-B571BD4361E7Q34152234-5E160354-CD0F-4307-BE8D-B8E9F91A91F3Q34187046-E8E33DB4-D4CA-4C62-8D09-8BF6387EE3D4Q34283696-26BBCE06-2A86-4684-AFD9-14E0013D1962Q34310582-868F0EFC-CF41-460A-91FA-0384854B60CDQ34335370-84A01CB0-8EB4-4CE5-99F9-2592A57C8591Q34339729-70469F49-598B-4DD7-8042-AA7683129CC2Q34411111-4B209051-766F-4C78-82C0-68D07182D9DBQ34477498-B03B2987-4D3D-474D-8EBC-13C136579F93Q34546550-4BB0AD84-2D0B-4EEC-8A0B-24A620218DF7Q34551969-528AA423-526D-42B3-B21E-D036A592F0FDQ34583160-83C1BB33-097B-4F52-9304-3853651B318CQ34593100-8013FC59-F68D-4D9F-BCFF-ED8DC601BBBBQ34601418-14D9DAF0-85F7-469E-BBFE-C4752B90280EQ34622812-DDE900C3-058C-4588-94DA-BC7346CB6388Q34657561-58A7D3B4-B5D6-496C-A86C-B5494F4840DBQ34699968-F67D6635-DEB7-41AD-AA0B-3ACA9C97DA49Q34953499-4155109E-A253-4A44-B8DB-B27733517DEE
P2860
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Comparison of human papillomav ...... following incident infection.
@en
Comparison of human papillomav ...... following incident infection.
@nl
type
label
Comparison of human papillomav ...... following incident infection.
@en
Comparison of human papillomav ...... following incident infection.
@nl
prefLabel
Comparison of human papillomav ...... following incident infection.
@en
Comparison of human papillomav ...... following incident infection.
@nl
P2093
P356
P1476
Comparison of human papillomav ...... following incident infection.
@en
P2093
Galloway DA
Koutsky LA
P304
P356
10.1086/315498
P407
P577
2000-05-31T00:00:00Z